Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy
Open Access
- 15 February 2001
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 107 (4) , 431-438
- https://doi.org/10.1172/jci11526
Abstract
To initiate infection, HIV-1 requires a primary receptor, CD4, and a secondary receptor, principally the chemokine receptor CCR5 or CXCR4. Coreceptor usage plays a critical role in HIV-1 disease progression. HIV-1 transmitted in vivo generally uses CCR5 (R5), but later CXCR4 (X4) strains may emerge; this shift heralds CD4+ cell depletion and clinical deterioration. We asked whether antiretroviral therapy can shift HIV-1 populations back to R5 viruses after X4 strains have emerged, in part because treatment has been successful in slowing disease progression without uniformly suppressing plasma viremia. We analyzed the coreceptor usage of serial primary isolates from 15 women with advanced disease who demonstrated X4 viruses. Coreceptor usage was determined by using a HOS-CD4+ cell system, biological and molecular cloning, and sequencing the envelope gene V3 region. By constructing a mathematical model to measure the proportion of virus in a specimen using each coreceptor, we demonstrated that the predominant viral population shifted from X4 at baseline to R5 strains after treatment. Multivariate analyses showed that the shift was independent of changes in plasma HIV-1 RNA level and CD4+ cell count. Hence, combination therapy may lead to a change in phenotypic character as well as in the quantity of HIV-1. Shifts in coreceptor usage may thereby contribute to the clinical efficacy of anti-HIV drugs.Keywords
This publication has 31 references indexed in Scilit:
- Recovery of Replication‐Competent Virus from CD4 T Cell Reservoirs and Change in Coreceptor Use in Human Immunodeficiency Virus Type 1–Infected Children Responding to Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- Unexpected Coreceptor Usage of Primary Human Immunodeficiency Virus Type 1 Isolates from Viremic Patients under Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- Clinical and Immunologic Response without Decrease in Virus Load in Patients with AIDS after 24 Months of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 1999
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected IndividualsThe Journal of Experimental Medicine, 1997
- Molecular Cloning of Full-Length HIV-1 Genomes Directly from Plasma Viral RNAJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion CofactorsCell, 1996
- Positioning of Positively Charged Residues in the V3 Loop Correlates with HIV Type 1 Syncytium-Inducing PhenotypeAIDS Research and Human Retroviruses, 1996
- In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosineAIDS, 1995